Please login to the form below

Not currently logged in
Email:
Password:

Triple negative breast cancer

This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... The therapy is now indicated as monotherapy for the treatment of adults with unresectable (cannot be removed by

Latest news

More from news
Approximately 9 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Patient diversity in clinical trials needs to be centre stage Patient diversity in clinical trials needs to be centre stage

    For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic

  • Deal Watch January 2018

    The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug

  • Pharma deals during February 2014 Pharma deals during February 2014

    awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...